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Background: There is a lack of data concerning socioeconomic outcome and quality of 
life (QoL) in patients after status epilepticus (SE) in Germany.
Patients and methods: Adult patients treated between 2011 and 2015 due to SE at 
the university hospitals in Frankfurt, Greifswald, and Marburg were asked to fill out a 
questionnaire regarding long-term outcome of at least 3 months after discharge. The 
SE cohort consisted of 25.9% patients with an acute symptomatic, 42% with a remote 
symptomatic and previous epilepsy, 22.2% with a new-onset remote symptomatic, and 
9.9% with other or unknown etiology. A matched case–control analysis was applied for 
comparison with patients with drug refractory epilepsy and seizure remission, both not 
previously affected by SE.
results: A total of 81 patients (mean age: 58.7 ± 18.0 years; 58% female) participated. 
A non-refractory course was present in 59.3%, while 27.2% had a refractory SE (RSE) 
and 13.6% had a superrefractory SE (SRSE). Before admission, a favorable modified 
Rankin Scale (mRS) of 0–3 was found in 82.7% (67/81), deteriorating to 38.3% (31/81) 
(p = 0.003) at discharge. The majority returned home [51.9% (42/81)], 32.1% entered 
a rehabilitation facility, while 12.3% were transferred to a nursing home and 3.7% to 
another hospital. The overall mRS at follow-up did not change; 61.8% (45/74) reached 
an mRS of 0–3. In RSE and SRSE, the proportion with a favorable mRS increased from 
45.5% at discharge to 70% at follow-up, while QoL was comparable to a non-refractory 
SE course. Matched epilepsy controls in seizure remission were treated with a lower 
mean number of anticonvulsants (1.3 ± 0.7) compared to controls with drug refractory 
epilepsy (1.9 ± 0.8; p < 0.001) or SE (1.9 ± 1.1; p < 0.001). A major depression was 
found in 32.8% of patients with SE and in 36.8% of drug refractory epilepsy, but only in 
20.3% of patients in seizure remission. QoL was reduced in all categories (QOLIE-31) 
in SE patients in comparison with patients in seizure remission, but was comparable to 
patients with drug refractory epilepsy.
Discussion: Patients after SE show substantial impairments in their QoL and daily 
life activities. However, in the long term, patients with RSE and SRSE had a relatively 
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favorable outcome comparable to that of patients with a non-refractory SE course. This 
underlines the need for efficient therapeutic options in SE.
Keywords: epilepsy, seizure, anticonvulsants, morbidity, mortality
inTrODUcTiOn
Status epilepticus (SE) presents as a major neurological emergency 
and is associated with a substantial burden on individuals and 
society (1–3). Prolonged inpatient treatment and neurological 
sequelae due to SE lead to substantial direct and indirect costs 
and result in reduced quality of life (QoL). Rehabilitation and 
informal care are often necessary following discharge from acute 
treatment and might result in further costs. Studies on outcome 
show a substantial portion of patients who are discharged with 
a neurologic deficit, while overall hospital mortality is about 
15–20%. Both SE related morbidity and mortality increase with 
a refractory course and prolonged inpatient treatment (4–6). 
Prehospital and in-hospital treatment strategies aim at a timely 
cessation of seizure activity and consist of benzodiazepines, intra-
venous anticonvulsants, and anesthetic drugs in selected cases (7).
Given the reduced QoL and increased rate of depression in 
patients with drug refractory epilepsy, as proven by several studies 
(8–11), patients with SE are very likely to suffer from decreased 
QoL and mood disorders. However, there is a paucity of data 
concerning socioeconomic outcome and QoL in patients after an 
SE, especially as there is no study on this topic from Germany.
Thus, the objective of this multicenter study is to determine 
the outcome, resource utilization, and QoL indicators following 
an episode of SE. For comparison, patients suffering from epilepsy 
who had never previously experienced an episode of SE were 
matched by age and gender: we matched two groups, one with a 
drug refractory epilepsy (DRE) and one with epilepsy patients in 
seizure remission (SRE) for more than 1 year as they show distinct 
outcomes regarding QoL, health resource utilization, and mood 
disorders.
PaTienTs anD MeThODs
study settings and Design
This longitudinal study on outcome, QoL, and resource utiliza-
tion was performed by means of a bottom-up approach from the 
perspective of the statutory health insurer at the university hos-
pitals in Frankfurt am Main, Greifswald, and Marburg. The study 
was granted approval by the local ethics committees and regis-
tered at the German Clinical Trials Register (DRKS00008718). 
The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines were followed (12).
Adult patients of 18  years or older treated due to SE at the 
participating university hospitals during the 5-year study period 
of 2011–2015 were asked to fill out a questionnaire regarding 
long-term outcome for at least 3 months after discharge. Overall, 
669 patients were treated due to SE during the study period with 
an average in-hospital mortality of 18.8% (n = 126). Therefore, 
responder rate was 15% regarding 81 of 543 survivors. The 
questionnaire was validated for use in people with epilepsy 
(13, 14). Patients with SE received standard care with no 
intervention due to the study, and a decision for rehabilitation 
after SE was at the discretion of the treating physician. An opera-
tional definition consistent with ILAE guidelines was adopted 
that defines convulsive SE as ≥5 min of continuous seizure or two 
or more discrete seizures, between which there is an incomplete 
recovery (15, 16). In case of focal SE or absence SE, the definition 
encompassed at least 5 min of seizure duration; however, none of 
the patients were identified with a focal SE or absence SE below 
duration of 20 min (1). Refractory SE (RSE) was defined as recur-
rent seizure activity despite two appropriately selected and dosed 
antiepileptic drugs, including benzodiazepine, and superrefrac-
tory SE (SRSE) was referred to as a SE that continues or recurs 
24  h or more after the initiation of treatment with anesthetic 
drugs, including cases in which seizure control is attained after 
induction of anesthesia, but recurs on weaning the patient off the 
anesthetic agent (4, 17, 18). Patients were assigned to four major 
groups based on etiology and onset of SE with (1) acute sympto-
matic SE, due to an acute brain injury as defined by the ILAE (19); 
(2) new-onset, remote symptomatic SE, with no history of epilepsy 
or SE; (3) remote symptomatic SE, with history of epilepsy or SE; 
and (4) other etiologies, such as idiopathic generalized epilepsy or 
progressive symptomatic causes. The epilepsy diagnosis was based 
on the definitions proposed by the ILAE and the International 
Bureau for Epilepsy (20). Patients were excluded if the diagnosis 
of SE could not be unequivocally determined, or if SE was due to 
hypoxia after cardiopulmonary resuscitation.
We employed a matched case–control analysis to compare the 
SE group with two control groups of epilepsy patients, either with 
drug refractory epilepsy (DRE) or in seizure remission (SRE) for 
more than 1 year. None of the patients from the epilepsy control 
groups suffered from an SE during their lifetime. Patients were 
matched by age and gender. The distribution of age and gender did 
not differ significantly across the groups, except for SRE patients, 
who were, in mean, 2 years younger than patients in the SE group.
instruments
To analyze the health-related QoL, we used scales, such as Quality 
of Life in Epilepsy Inventory (QOLIE-31) (21), Neurological 
Disorders Depression Inventory for Epilepsy (NDDI-E) (22), A-B 
neuropsychological assessment schedule (ABNAS, originally the 
A-B neurotoxicity scale) (23), Liverpool Adverse Events Profile 
(LAEP) (24), and the EuroQol questionnaire (EQ-5D) (25). 
Measures of severity of illness and long-term outcome included 
the modified Rankin Scale (mRS) (26) on admission, discharge, 
and follow-up. Healthcare resource utilization is reported as use 
of inpatient, outpatient, rehabilitation, and anticonvulsive treat-
ment. For cost unit data and details of evaluation, please refer to 
previous publications (27, 28).
Data entry and statistical analysis
Statistical analyses were performed using IBM SPSS Statistics, 
version 22.0 (IBM Corp., Armonk, NY, USA). Most data are 
TaBle 1 | Socioeconomic and clinical characteristics in patients with SE 
provided for all patients (n = 81) and according to a non-RSE (n = 48) and RSE 
or SRSE course (n = 33).
all patients 
with se 
(n = 81)
non-rse 
(n = 48)
rse/srse 
(n = 33)
p Valuea
Age (years) at admission
Mean ± SD 58.7 ± 18.0 61.8 ± 16.8 54.2 ± 18.9 0.063
Range 21–97 23–97 21–80
Sex % (n) % (n) % (n)
Male 42.0 (34) 35.4 (17) 51.5 (17) 0.225
Female 58.0 (47) 64.6 (31) 48.5 (16)
Etiology % (n) % (n) % (n)
Acute symptomatic 25.9 (21) 16.7 (8) 39.4 (13) 0.021
Remote symptomatic 42.0 (34) 43.8 (21) 39.4 (13) (Acute 
vs non-
acute)
New onset SE 22.2 (18) 27.1 (13) 15.2 (5)
Other or unknown 9.9 (8) 12.5 (6) 6.1 (2)
mRS at admission % (n) % (n) % (n)
mRS 0–3 82.7 (67) 81.3 (39) 84.8 (28) 0.673
mRS 4–5 17.3 (14) 18.8 (9) 15.2 (5)
mRS at discharge % (n) % (n) % (n)
mRS 0–3 61.7 (50) 72.9 (35) 45.5 (15) 0.012
mRS 4–5 38.3 (31) 27.1 (13) 54.5 (18)
mRS at follow-up % (n) % (n) % (n)
mRS 0–3 60.8 (45) 54.5 (24) 70.0 (21) 0.180
mRS 4–5 39.2 (29) 45.5 (20) 30.0 (9)
Discharge destination % (n) % (n) % (n)
Home 51.9 (42) 64.6 (31) 33.3 (11) 0.013
Rehabilitation 32.1 (26) 16.7 (8) 54.5 (18) (home 
vs other)
Other hospital 3.7 (3) 2.1 (1) 6.1 (2)
Nursing home 12.3 (10) 16.7 (8) 6.1 (2)
Living situation % (n) % (n) % (n)
At home without help 25.9 (21) 27.1 (13) 24.2 (8) 0.732
At home with help 
(family, nursing, etc.)
54.0 (43) 47.9 (23) 60.6 (20)
Nursing home 19.8 (16) 22.9 (11) 15.2 (5)
n.a. (1) (1)
Care level % (n) % (n) % (n)
None 33.3 (27) 33.3 (16) 33.3 (11) 0.947
None, but in need 
of care
8.6 (7) 10.4 (5) 6.1 (2)
Care level existing 56.8 (46) 54.2 (26) 60.6 (20)
n.a. (1) (1)
Grade of disability % (n) % (n) % (n)
Yes 79.0 (64) 79.2 (38) 78.8 (26) 0.820
None 19.8 (16) 18.8 (9) 21.2 (7)
n.a. (1) (1)
Number of AEDs at 
discharge
% (n) % (n) % (n)
0 1.2 (1) - 3.0 (1)
1 33.3 (27) 43.8 (21) 18.2 (6)
2 32.1 (26) 35.4 (17) 27.3 (9)
≥3 33.3 (27) 20.8 (10) 51.5 (17)
Total (mean ± SD) 2.1 ± 1.0 1.8 ± 0.9 2.5 ± 1.1 0.007
Number of AEDs at 
follow-up
% (n) % (n) % (n)
0 4.2 (3) 2.4 (1) 6.7 (2)
1 40.3 (29) 50.0 (21) 26.7 (8)
2 19.4 (14) 23.8 (10) 13.3 (4)
≥3 36.1 (26) 23.8 (10) 53.3 (16)
Total (mean ± SD) 1.9 ± 1.1 1.8 ± 1.0 2.2 ± 1.1 0.113
(Continued)
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presented as percentage or mean ±  SD and as minimum and 
maximum. Comparisons between groups were accomplished 
using adequate parametric and non-parametric tests. Since the 
study was planned to have an explorative nature, no further 
adjustment for multiple testing was performed.
resUlTs
characteristics of Patients with se
During the 5-year study period, a total of 81 patients (mean age: 
58.7 ± 18.0 years, range: 21–97 years; 58.0% female) participated 
in the study. An acute symptomatic etiology was present in 25.9% 
(n  =  21), a remote symptomatic SE was attributed in 22.2% 
(n = 18) with new-onset SE, and in 42.0% (n = 34) of patients 
with history of epilepsy, other or unknown etiologies were seen 
in 9.9% (n = 8). Of these cases, 59.3% (n = 48) had a non-RSE, 
27.2% (n = 22) an RSE, and 13.6% (n = 11) had an SRSE. Details 
of clinical or socioeconomic characteristics and QoL at least 
3 months after SE are provided in Table 1.
Before admission, a favorable mRS of 0–3 was present in 82.7% 
(n = 67), while an unfavorable mRS of 4–5 was seen in 17.3% 
(n =  14) of the SE population. On discharge, mRS decreased 
significantly with 31 patients (38.3%, p  =  0.003) rated at an 
unfavorable mRS of 4–5. The mRS at follow-up did not differ 
from the one at discharge; 60.8% (45/74) presented an mRS of 
0–3 and 39.2% (29/74) an mRS of 4–5 (Figure 1); seven patients 
did not report their mRS on follow-up. Regarding RSE and SRSE, 
a favorable mRS of 0–3 was present in 45.5% at discharge and 
increased to 70% at follow-up.
At discharge, the majority returned home (51.9%, n =  42), 
32.1% (n = 26) entered a rehabilitation facility, 12.3% (n = 10) 
were transferred into a nursing home, and 3.7% (n = 3) to another 
hospital. At the time of follow-up, 21 patients (25.9%) lived at 
home without any help, 43 (54%) depended on aid of their fami-
lies, and partners or of ambulatory nursing care, while 16 patients 
(19.8%) lived in a nursing home. A care level (Pflegestufe) was 
attributed to 56.8% and a grade of disability to 79% of the SE 
patients. Only 9 of 49 patients of working age (18.4%) had been 
employed at follow-up.
Regarding healthcare resource utilization within the last 
3  months, an ambulance transport to hospital was necessary 
in 13.2%. The mean number of outpatient consultations due to 
epilepsy amounted to 3.1 ±  3.3 (range 1–17). Overall, 22.5% 
(n = 18/81) of the SE patients were hospitalized due to epilepsy 
for a mean of 6.8 days within the last 3 months. Patients were in 
need of ancillary therapies, such as physiotherapy, occupational 
therapy, or speech therapy, with a mean number of 22.1 ± 18.3 
(range 1–80) sessions within the previous 3 months. The number 
of AEDs did not differ at follow-up compared to discharge (see 
Figure 2).
The evaluation of QoL using the EQ-5D-Index showed 
0.57 ± 0.36 on average (0 = death to 1 =  full health). Most of 
the patients showed impairments due to side effects of anti-
convulsants; the mean ABNAS score amounted to 34.9 ±  20.8 
and 73.6% of the patients reported a high score (ABNAS 0–99, 
99 = the worst score, >15=high score, and ≤15=low score) (23). 
FigUre 1 | Modified Rankin Scale (mRS) at admission, discharge, and follow-up in patients with status epilepticus.
all patients 
with se 
(n = 81)
non-rse 
(n = 48)
rse/srse 
(n = 33)
p Valuea
Healthcare resource utilization within the last 3 months
Inpatient treatment due 
to epilepsy
% (n) % (n) % (n)
Yes 22.2 (18) 17.0 (8) 30.3 (10) 0.146
None 77.7 (63) 83.0 (40) 69.7 (23)
Outpatient hospital 
treatment due to 
epilepsy
% (n) % (n) % (n)
Yes 14.3 (11) 11.1 (5) 18.8 (6) 0.316
None 85.7 (70) 88.9 (43) 81.3 (27)
NDDI-E % (n) % (n) % (n)
Major depression 
(Score >15)
32.8 (19) 30.3 (10) 36.0 (9) 0.647
No major depression 
(Score ≤15)
67.2 (39) 69.7 (23) 64.0 (16)
ABNAS
Total (mean ± SD) 34.9 ± 20.8 34.6 ± 20.1 35.2 ± 22.0 0.351
Range 0–72 3–71 0–72
LAEP
Total (mean ± SD) 41.9 ± 10.4 41.5 ± 10.3 42.3 ± 10.8 0.997
Range 14–63 20–62 14–63
QOLIE-31
Overall T (mean ± SD) 43.5 ± 13.7 44.2 ± 13.9 42.5 ± 13.6 0.870
Range 11–73 11–73 16–66
VAS (mean ± SD) 48.3 ± 24.5 49.2 ± 22.7 47.2 ± 27.0 0.618
aComparison between non-RSE and RSE/SRSE.
SE, status epilepticus; RSE, refractory SE; SRSE, superrefractory SE; mRS, modified 
Rankin Scale; AEDs, antiepileptic drugs; NIDDI-E, Neurological Disorders Depression 
inventory for Epilepsy; LAEP, Liverpool Adverse Events Profile; QOLIE, Quality of Life 
in Epilepsy Inventory; VAS, visual analog scale; ABNAS, A-B neuropsychological 
assessment schedule.
TaBle 1 | Continued
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Table 1 presents the socioeconomic characteristics and QoL in 
relation to the severity of SE. Admissions were more likely due 
to an acute symptomatic etiology in patients with RSE or SRSE 
(39.4%) than with a non-refractory course (16.7%, p =  0.021). 
Furthermore, the course of SE had a significant impact on the 
degree of disability, as measured by mRS at discharge [mRS 0–3 in 
72.9% (35/48) vs 45.5% (15/33); p = 0.012]. Patients with RSE and 
SRSE were discharged with more AEDs [2.5 ± 1.1 (mean ± SD) 
vs 1.8 ± 0.9; p = 0.007], while this difference was not detectable 
at follow-up (p = 0.113). Patients with non-RSE were more fre-
quently discharged home (64.6 vs 33.3%; p = 0.013), while more 
patients with RSE or SRSE were transferred into a rehabilitation 
center (54.5 vs 16.7%; p < 0.001). Concerning the QoL, patients 
after an RSE or SRSE achieved the same outcome as patients with 
a non-refractory course, as measured by NDDI-E, ABNAS, LAEP, 
QOLIE-31, or VAS.
comparison of Qol between Patients 
after se and Patients with Drug refractory 
epilepsy and in seizure remission
For each patient after SE, one patient with DRE and one with SRE 
were matched by age and gender. The mean length of epilepsy 
amounted to 19.9 ± 17.6 years in DRE and to 17.0 ± 16.0 years 
in SRE. SE patients had a significantly shorter length of epi-
lepsy (9.3 ± 14.2 years, p < 0.001 DRE and p = 0.001 SRE) at 
follow-up.
Table 2 shows the socioeconomic and clinical characteristics 
and QoL of SE patients at follow-up compared to patients with 
DRE and SRE. In the two control groups, significantly more 
patients lived at home independently than in the SE group 
FigUre 2 | Number of used anticonvulsants at admission, discharge, and follow-up in patients with status epilepticus. AEDs, antiepileptic drugs.
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(SE: 25.9%; DRE: 46.3%; p =  0.008, SRE: 64.6%; p <  0.001), 
in particular, in the cohort with SRE, no patient lived in a 
nursing home. Concerning marital status, 70.3% of patients 
with SRE were married in comparison to 55.6% (p = 0.048) of 
patients in the SE cohort. The mRS at follow-up documented a 
better state of health for both control groups (mRS 0–3: DRE 
98.8%, SRE 97.5%) in comparison to the SE group (mRS 0–3 in 
60.8%; p < 0.001 each). Regarding epilepsy-related healthcare 
resource utilization, about 22.2% (n = 18) of the SE patients 
were treated in a hospital, whereas fewer patients with drug 
refractory epilepsy (11.1%; n =  9, p =  0.057) and with SRE 
(1.2%; n =  1, p <  0.001) were hospitalized due to epilepsy 
within the last 3  months. Mean length of stay amounted to 
6.8 ± 5.9 days (range 1–20) for SE, 7.0 ± 5.2 days (range 1–18) 
for DRE, and 7.0 days for SRE. An outpatient hospital treat-
ment due to epilepsy was necessary for 14.3% patients with 
SE, 23.8% of patients with DRE, and 7.9% of patients in SRE. 
Patients in SRE were treated with a mean number of 1.3 ± 0.7 
anticonvulsants (AEDs) and with significantly fewer AEDs 
than those with drug refractory epilepsy (1.9 ± 0.8; p < 0.001) 
or SE (1.9 ± 1.1; p < 0.001).
A major depression, as indicated by NDDI-E, was found in 
nearly one-third of patients with SE (32.8%) and DRE (36.8%), but 
only in 20.3% of patients with SRE. Side effects intensity evaluated 
by the LAEP score was 41.9 ± 10.4 in SE patients, 40.5 ± 11.8 in 
DRE patients, and lower in SRE patients (37.0 ± 11.8; p = 0.011). 
A better QoL, measured by QOLIE-31 and VAS, was seen for 
patients in SRE in all categories compared to patients after 
SE. Regarding the subcategory QoL, both patients with DRE 
(p = 0.013) and SRE (p < 0.001) scored better than patients after 
SE; for details, please refer to Table 2.
DiscUssiOn
This study on QoL and socioeconomic outcome after an episode 
of SE is the first comprehensive evaluation to address sequelae 
and outcome of adult patients with SE and compare them with 
matched epilepsy controls with a drug refractory course or in 
SRE. We can show that patients with RSE and SRSE had a dete-
rioration in neurological functions at discharge, which can be set 
off at follow-up. Furthermore, patients after RSE and SRSE may 
achieve an equivalent QoL compared to patients after a non-RSE. 
Despite persistent and increased neurological deficits in patients 
after SE, these patients may achieve similar QoL values to patients 
with DRE who have no neurological deficits. However, QoL was 
reduced in all subcategories of QOLIE-31 when compared to 
patients in SRE.
Our findings underline the need for an efficient therapy 
of RSE and SRSE, as these patients will, on average, achieve 
outcomes comparable to patients with a non-RSE and patients 
with DRE. That is remarkable as these patients are suffering from 
persisting neurological deficits, as measured by mRS, and show 
TaBle 2 | Socioeconomic and clinical characteristics of patients with SE in comparison to matched epilepsy patients with drug refractory course and in seizure 
remission (n = 81 in each group).
se (n = 81) Drug-resistant epilepsy 
(n = 81)
epilepsy in sre >1 year 
(n = 81)
p Value
Age (years) at survey
Mean ± SD 58.7 ± 18.0 57.3 ± 15.6 56.2 ± 14.0 0.082 (SE vs DRE)
Range 21–97 21–94 20–87 0.001 (SE vs SRE)
Sex % (n) % (n) % (n)
Male 42.0 (34) 42.0 (34) 42.0 (34) 1.0
Female 58.0 (47) 58.0 (47) 58.0 (47)
Marital status % (n) % (n) % (n)
Married or with partner 55.6 (45) 64.2 (52) 70.4 (57) 0.302 (SE vs DRE)
Divorced or in separation 6.2 (5) 7.4 (6) 9.9 (8) 0.048 (SE vs SRE)
Living with family/relatives 7.4 (6) 11.1 (9) 12.3 (10)
Widowed 29.6 (24) 17.3 (14) 6.2 (5)
n.a. (1) (1)
Living situation % (n) % (n) % (n)
At home without help 25.9 (21) 45.7 (37) 62.9 (51) 0.008 (SE vs DRE)
At home with help (family, nursing service) 54.0 (43) 50.6 (41) 34.6 (28) <0.001 (SE vs SRE)
Nursing home 19.8 (16) 2.5 (2) –
n.a. (1) (1) 2.5 (2)
mRS at follow-up % (n) % (n) % (n)
mRS 0–3 60.8 (45) 98.8 (80) 97.5 (79) <0.001 each
mRS 4–5 39.2 (29) 1.2 (1) 2.5 (2)
Number of AEDs at follow-up % (n) % (n) % (n)
0 4.2 (3) – 4.9 (4)
1 40.3 (29) 40.7 (33) 65.4 (53)
2 19.4 (14) 35.8 (29) 25.9 (21)
≥3 36.1 (26) 23.5 (19) 3.7 (3)
Number of AEDs (mean ± SD) 1.9 ± 1.1 1.9 ± 0.8 1.3 ± 0.7 0.632 (SE vs DRE); <0.001 (SE vs SRE)
Healthcare resource utilization within the last 3 months
Inpatient treatment due to epilepsy % (n) % (n) % (n)
Yes 22.2 (18) 11.1 (9) 1.2 (1) 0.057 (SE vs DRE)
None 77.7 (63) 88.9 (72) 98.8 (80) <0.001 (SE vs SRE)
Length of stay (mean ± SD) 6.8 ± 5.9 7.0 ± 5.2 7.0
Outpatient hospital treatment due to epilepsy % (n) % (n) % (n)
Yes 14.3 (11) 23.8 (19) 7.9 (6) 0.105 (SE vs DRE)
None 85.7 (70) 76.3 (62) 92.1 (75) 0.2 (SE vs SRE)
NDDI-E % (n) % (n) % (n)
Major depression (>15 points) 32.8 (19) 36.8 (21) 20.3 (12) 0.79 (SE vs DRE)
No major depression (≤15 points) 67.2 (39) 63.2 (36) 79.7 (47) 0.128 (SE vs SRE)
LAEP % (n) % (n) % (n)
Total score (mean ± SD) 41.9 ± 10.4 40.5 ± 11.8 37.0 ± 11.8 0.375 (SE vs DRE)
Range 14–63 19–69 19–45 0.011 (SE vs SRE)
QOLIE-31 (1–100, 100 best QoL) % (n) % (n) % (n)
Overall T 43.5 ± 13.7 44.8 ± 12.8 51.8 ± 12.5 0.698 (SE vs DRE); <0.001 (SE vs SRE)
Quality of Life T 41.7 ± 11.5 46.6 ± 9.7 50.2 ± 11.2 0.013 (SE vs DRE); <0.001 (SE vs SRE)
Seizure Worry T 51.3 ± 12.3 48.9 ± 10.5 56.0 ± 9.7 0.084 (SE vs DRE); 0.042 (SE vs SRE)
Emotional Well-Being T 43.8 ± 11.2 46.3 ± 10.7 49.4 ± 10.8 0.296 (SE vs DRE); 0.009 (SE vs SRE)
Energy-Fatigue T 43.6 ± 9.2 46.3 ± 9.8 49.6 ± 10.1 0.114 (SE vs DRE); 0.002 (SE vs SRE)
Cognitive Functioning T 45.8 ± 12.6 46.8 ± 12.0 50.6 ± 11.9 0.832 (SE vs DRE); 0.011 (SE vs SRE)
Medication Effects T 49.0 ± 10.7 50.8 ± 9.6 53.8 ± 9.3 0.328 (SE vs DRE); 0.011 (SE vs SRE)
Social Functioning T 44.3 ± 11.8 45.2 ± 10.5 52.0 ± 10.4 0.909 (SE vs DRE); <0.001 (SE vs SRE)
VAS (mean ± SD) 48.3 ± 24.5 55.3 ± 22.9 65.3 ± 22.1 0.269 (SE vs DRE)
<0.001 (SE vs SRE)
AEDs, antiepileptic drugs; SE, status epilepticus; DRE, drug refractory epilepsy; mRS, modified Rankin Scale; NIDDI-E, Neurological Disorders Depression Inventory for Epilepsy; 
LAEP, Liverpool Adverse Events Profile; QOLIE, Quality of Life in Epilepsy Inventory; VAS, visual analog scale; SRE, seizure remission.
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an increased need for assistance in daily activities. Furthermore, 
patients with RSE and SRSE improve in neurological outcome 
over time. This is in line with previous findings, as reported by 
Lai et al. (29). They reported functional outcome using the mRS 
in patients with prolonged RSE on admission, discharge, and 
1  year after discharge. In their cohort, a favorable outcome of 
mRS 0–3 increased from 11.5% of patients at discharge to 17.1% 
of patients at follow-up (29). Ferlisi and Shorvon reported on 
long-term outcomes of RSE and SRSE, providing mortality 
rates and data on neurologic defects in 596 cases (4). Overall, 
35% of the patients were able to return to baseline, while 13% 
suffered a severe neurologic deficit, a further 13% had a mild 
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neurologic deficit and 4% had an undefined neurologic deficit. 
Mortality accumulated to 35% (4). The preliminary report of the 
global audit from 44 countries on treatment of RSE and SRSE 
(30) showed a favorable outcome with an mRS of 0–3 in 36% 
of the patients at discharge (26.6% =  mRS 0–2; 9.4% =  mRS 
3), which improved to 63.8% at follow-up (42.6% = mRS 0–2; 
21.3% = mRS 3). The follow-up was available for 108 patients 
with an obvious selection bias, as noted by the authors.
A retrospective study from India used the Glasgow Outcome 
Scale (GOS) to describe outcome. They reported that SRSE had 
a worse outcome after 6 months in comparison with RSE (33.3 
vs 57.1%; p = 0.055) and non-RSE (33.3 vs 79.1%; p < 0.0001) 
(31). These findings are well explained by encephalitis as the 
main underlying etiology in SRSE cases reported from India, 
an etiology that is independently associated with a poor 
outcome.
Sutter et  al. reported on identification of predictors for 
outcome involving clinical features such as age, history of prior 
seizures or epilepsy, SE etiology, level of consciousness, and 
seizure type at SE onset (6). Determination of predictors from 
our study is hindered by the limited sample size. However, overall 
mortality rates of the overall SE group and outcome measures 
(mRS or GOS) are in line with previous publications (4, 5, 29, 31).
Patients after SE achieved QoL scores comparable to 
patients with DRE who had never suffered from SE. Given 
the neurological deficits in the SE group, these seem rather 
surprising. Strong determinants of reduced QoL in DRE are 
depression and anxiety, as shown by multiple studies (9, 32, 33). 
Furthermore, tolerability and efficacy of AEDs, employment, 
seizure frequency and semiology, and comorbidities will influ-
ence some aspects of QoL in DRE (9, 32–35). These factors are 
also present in patients after SE, e.g., depression in one-third of 
our SE cohort, and should be kept in mind during rehabilita-
tion and further outpatient treatment. Use of inpatient and 
outpatient services after SE remains high, showing the ongoing 
need for neurological care to this potentially vulnerable patient 
group. Most of the studies on outcome of SE focused on the 
first months to a year after discharge, which might influence 
the QoL outcome. DRE patients in our study suffered for two 
decades from epilepsy, which likely explains some of the dete-
rioration in QoL.
limitations of the study
Despite a careful design and strong efforts to gather follow-up 
data, this study has certain limitations. Direct comparison to 
other studies is difficult because of different healthcare settings, 
differences in etiology between different regions, age considera-
tions (children are not included in our study), and varying treat-
ment approaches. Definition of RSE might differ among studies 
with varying amount of drugs or time passed to define an SE as 
being refractory.
Due to the study design, which implies a questionnaire that 
was filled out by patients or their families, we cannot exclude 
a misunderstanding sometimes leading to incorrect answers. 
Furthermore, results of this survey are probably biased by 
selection due to the SE-associated mortality (overall 18.8%) 
and morbidity that were also described in other studies (30). 
Morbidity and mortality after discharge might explain the low 
responder rate of 15%, and mortality at discharge and during 
follow-up might be the main confounder in our study. The 
average in-hospital mortality in our SE cohort is 5.8% for non-
RSE and 20.1% for RSE and SRSE (1) and matches nationwide 
evaluations of mortality in SE (3). We have to assume that par-
ticipating patients were able to write or communicate with their 
relatives to complete the questionnaire. Adults who depend on 
help of their family members, who live in a nursing home, or 
who suffer a severe disability might be underrepresented in this 
evaluation. As we used patient questionnaires to collect data 
regarding resource utilization, the possibility of incomplete 
patient recall in some of the categories cannot be excluded 
and could have resulted in an underestimation of resource use. 
Another limitation of the study is the relatively short evaluation 
period of 3 months, which could have led to large variability 
in estimates.
cOnclUsiOn
Patients after SE show substantial impairments in their QoL and 
daily life activities. However, QoL is comparable to patients with 
DRE, despite more SE patients being affected by neurological 
deficits. Further studies and treatment evaluations are warranted 
to answer questions on the outcome of SE patients in the future, 
especially if new treatment strategies might improve initial out-
come and reduce in-hospital mortality. In the long term, patients 
with RSE and SRSE might have a favorable outcome regarding 
QoL and neurological functions compared to patients with a 
non-refractory course. This underlines the need for efficient 
therapeutic options in these challenging situations.
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